ipilimumab-non-small-cell-lung-cancer

Ipilimumab in Non-Small Cell Lung Cancer

Drug class	Target	Agent	Diseases	Line of Therapy	Status	Source
CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody	CTLA-4	ipilimumab (Yervoy)	non-small cell lung cancer	metastatic	Trials complete with results	Lynch et al. 2012

The efficacy and safety of anti-CTLA-4 molecules for the treatment of patients with non-small cell lung cancer (NSCLC) is currently under investigation. Ipilimumab has shown promise in treating patients with metastatic NSCLC in one phase II trial (Lynch et al. 2012). This has led to ongoing phase III trials of ipilimumab in the treatment of patients with metastatic NSCLC (NCT01285609; Langer 2014).

Reference	Study Type / Phase	Line of Treatment	Treatment Agent	# Patients in Study	Response Rate	PFS (months)	OS (months)
Lynch et al. 2012	Phase II	1st	concurrent ipilimumab + carboplatin + paclitaxel	70	21%	4.1	9.7
			phased ipilimumab + carboplatin + paclitaxel	68	32%	5.1	12.2
			carboplatin + paclitaxel	66	14%	4.2	8.3

NOTE: OS = overall survival; PFS = progression-free survival

Contributors: Wade T. Iams, M.D., Douglas Johnson, M.D., Christine M. Lovly, M.D., Ph.D.

Suggested Citation: Iams, W.T., D. Johnson, C. Lovly. 2015. Immunotherapy in Cancer. My Cancer Genome http://www.mycancergenome.org/content/molecular-medicine/c2654-non-small-cell-lung-cancer/ (Updated February 10).

Last Updated: June 24, 2015

Disclaimer: The information presented at MyCancerGenome.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.